Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

The present disclosure discloses a deuterated organic compound and a formulation and an organic electronic device containing the same, wherein the deuterated organic compound has the following structural formula:

##STR00001##

wherein Ar is an aromatic or heteroaromatic structural unit, D is an electron donor group, A is an electron acceptor group, n and m are an integer between 1 and 6; and wherein for the organic compound, (S1-T1)≦0.25 eV, and at least one H atom of the organic compound is substituted by deuterium. The present disclosure achieves the improvement of the electroluminescence quantum efficiency and the lifetime of the organic compound by replacing the H atom in the organic compound with deuterium and having (S1-T1)≦0.35 eV, and the material of the present disclosure has a great application potential and application range due to its low cost and relatively simple synthesis process.

Embodiments provide a heterocyclic compound, a light-emitting device that includes the heterocyclic compound, and an electronic apparatus that includes the light-emitting device. The light-emitting device includes a first electrode, a second electrode facing the first electrode, an interlayer between the first electrode and the second electrode and including an emission layer, and at least one of the heterocyclic compound. The heterocyclic compound is represented by Formula 1, which is explained in the specification:

##STR00001##

Embodiments provide a heterocyclic compound, a light-emitting device that includes the heterocyclic compound, and an electronic apparatus that includes the light-emitting device. The light-emitting device includes a first electrode, a second electrode facing the first electrode, an interlayer between the first electrode and the second electrode and including an emission layer, and at least one of the heterocyclic compound. The heterocyclic compound is represented by Formula 1, which is explained in the specification:

##STR00001##

Disclosed are a heterocyclic compound represented by Formula 1-1 or 1-2,

##STR00001## wherein, in Formulae 1-1 and 1-2, X.sub.1, CY.sub.1 to CY.sub.3, R.sub.1 to R.sub.3, and a1 to a3, are the same as described in the specification. Also disclosed is an organic light-emitting device including the same.

Disclosed are a heterocyclic compound represented by Formula 1-1 or 1-2,

##STR00001## wherein, in Formulae 1-1 and 1-2, X.sub.1, CY.sub.1 to CY.sub.3, R.sub.1 to R.sub.3, and a1 to a3, are the same as described in the specification. Also disclosed is an organic light-emitting device including the same.

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

The present invention is related to a novel pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a process for preparing the same, and a pharmaceutical composition using the same.

The present invention is related to a novel pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a process for preparing the same, and a pharmaceutical composition using the same.